BEIJING (Bloomberg):- A newly approved Chinese drug for Alzheimer's will start clinical trials in the United States and Europe next year as the country's first novel therapy for the incurable disease seeks global legitimacy.
Shanghai Green Valley Pharmaceutical Co plans to recruit around 2,046 patients with mild to moderate Alzheimer's for trials at 200 sites across North America, Europe and Asia Pacific for 18 months, the company's vice-president Li Jinhe said on Sunday (Dec 29).
